Cited by 271Neutropenia and Cancer InfectionsChronic Lymphocytic Leukemia ResearchImmunodeficiency and Autoimmune Disorders

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

Open access

Varughese, Tilly, Taur, Ying, Cohen, Nina, Palomba, M Lia, Seo, Susan K, Hohl, Tobias M, Redelman-Sidi, Gil·2018·Clinical Infectious Diseases

DOI 10.1093/cid/ciy175PMC PMC6093991

Open this paper in CoChat — free account Open PDF

Abstract

Background: Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell lymphoma. Several case series have described opportunistic infections among ibrutinib recipients, but the full extent of these infections is unknown. We sought to determine the spectrum of serious infections associated with ibrutinib treatment. Methods: We reviewed the electronic medical records of patients with lymphoid cancer at Memorial Sloan Kettering Cancer Center who received ibrutinib during a 5-year period from 1 January 2012 to 31 December 2016. Serious infections were identified by review of the relevant microbiology, clinical laboratory, and radiology data. Risk factors for infection were determined by means of univariate and multivariate analyses. Results: We analyzed findings in 378 patients with lymphoid cancer who received ibrutinib. The most common underlying cancers were chronic lymphocytic leukemia and mantle cell lymphoma. 84% of patients received ibrutinib as monotherapy. Serious infection developed in 43 patients (11.4%), primarily during the first year of ibrutinib treatment. Invasive bacterial infections developed in 23 (53.5%) of these patients, and invasive fungal infections (IFIs) in 16 (37.2%) .The majority of patients with IFIs during ibrutinib therapy (62.5%) lacked classic clinical risk factors for fungal infection (ie, neutropenia, lymphopenia, and receipt of corticosteroids). Infection resulted in death in 6 of the 43 patients (14%). Conclusions: Patients with lymphoid cancer receiving ibrutinib treatment are at risk for serious infections, including IFIs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/cid/ciy175

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases
Vetrie, D. L. P., Vořechovský, I., Sideras, P., Holland, J., Davies, A. F., Flinter, F. A., Hammarström, L. L. G., Kinnon, C., Levinsky, R. J., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,465
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I. J., Sparkes, R. S., Kubagawa, H., Mohandas, T. K., Quan, S. G., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,326
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 3×
“Ibrutinib was approved by the US Food and Drug Administration for the treatment of patients with CLL, previously treated mantle cell lymphoma (MCL) or marginal zone lymphoma, WM, or refractory chronic graft-versus-host disease, and by the European Medicines Agency for the treatment of patients with CLL, WM, or previou…”
Method
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D. L., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 951
Self-citation
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 674
Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes
Thomas, J. D., Sideras, P., Smith, C. I. E., Vořechovský, I., Chapman, V. M., & Paul, W. E. (1993) · Science · doi:10.1126/science.8332900 · Cited by 613
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D. B., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 520

Flagged first, then by citations

Show all 36 references

Research works printed but not linked: 1

Smith, 1993–2018, X-linked agammaglobulinemia

Sorted by citations

Items 101–200 of 271

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
Nasillo, V., Lagreca, I., Vallerini, D., Barozzi, P., Riva, G., Maccaferri, M., Paolini, A., Forghieri, F., Fiorcari, S., Maffei, R., et al. (2022) · Cells · doi:10.3390/cells11061003 · Cited by 15
Cerebral aspergillosis in a patient on ibrutinib therapy—A predisposition not to overlook
Faisal, M. S., Shaikh, H. G., Khattab, A., Albrethsen, M., & Fazal, S. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218788717 · Cited by 15
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib
Cheng, M. P., Kusztos, A. E., Gustine, J. N., Dryden‐Peterson, S., Dubeau, T. E., Woolley, A. E., Hammond, S. P., Baden, L. R., Treon, S. P., Castillo, J. J., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15627 · Cited by 14
Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib
Malek, A. E., Nieto, Y. L., Szvalb, A. D., Siddiqui, S., Shafi, M. A., Hwang, J. P., RAAD, I. I., & Torres, H. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.006 · Cited by 14
On point in primary CNS lymphoma
Tsang, M., Cleveland, J. C., & Rubenstein, J. L. (2020) · Hematological Oncology · doi:10.1002/hon.2761 · Cited by 14
Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
Hillmen, P., Xie, J., Yong, A., Waweru, C., Sorof, T. A., Goyal, R., & Davis, K. L. (2021) · eJHaem · doi:10.1002/jha2.174 · Cited by 13
The infectious thyroid nodule: A case report of mucormycosis associated with ibrutinib therapy
Mascarella, M. A., Schweitzer, L., Alreefi, M., Silver, J. A., Çağlar, D., Loo, V. G., Richardson, K., Dufresne, P. J., Lee, T. C., & Sadeghi, N. (2019) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-019-0376-1 · Cited by 13
Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas
Pilmis, B., Kherabi, Y., Huriez, P., Zahar, J., & Mokart, D. (2023) · Cancers · doi:10.3390/cancers15071989 · Cited by 15
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
Naylor‐Adamson, L., Chacko, A. R., Booth, Z., Caserta, S., Jarvis, J., Khan, S., Hart, S. P., Rivero, F., Allsup, D. J., & Arman, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.766272 · Cited by 11
Disseminated Cryptococcal Infection in a Patient Receiving Acalabrutinib for Chronic Lymphocytic Leukemia
Wilson, P. A., & Melville, K. (2019) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000722 · Cited by 12
Riesgo de infección asociada a nuevas terapias para el tratamiento de los síndromes linfoproliferativos
Arcos, I. L., & Ruíz-Camps, I. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.07.026 · Cited by 12
The robust and rapid role of molecular testing in precision fungal diagnostics: A case report
Steinbrink, J. M., Hong, D. K., Bergin, S. P., Al-Rohil, R. N., Perfect, J. R., & Maziarz, E. K. (2020) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2020.02.003 · Cited by 12
Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review
Li, Z., Zheng, Z., Li, C., Li, Z., Wu, J., & Zhang, B. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1744157 · Cited by 12
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib
Holowka, T., Cheung, H., Malinis, M. F., Gan, G., Deng, Y., Perreault, S., Isufi, I., & Azar, M. M. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.08.005 · Cited by 12
High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma
Tey, A., Schwarer, J., Raffa, R., Shi, E., Paul, E. M., Opat, S., Dendle, C., & Shortt, J. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13928 · Cited by 10
Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning
Parviz, M., Agius, R., Rotbain, E. C., Vainer, N., Aarup, K., & Niemann, C. U. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2299737 · Cited by 11
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
Sun, K., Kasparian, S., Iyer, S. P., & Pingali, S. R. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.836 · Cited by 12
Exploiting antifungal immunity in the clinical context
Lionakis, M. S. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101752 · Cited by 12
Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies
Tham, K. W., Prelewicz, S., deHoll, S., Stephens, D. M., & Gómez, C. A. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad210 · Cited by 11
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report
Reddy, Y., Baig, M., Kalva, N. R., Puli, S. R., & Dhillon, S. (2020) · Cureus · doi:10.7759/cureus.7837 · Cited by 11
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies
Kin, A. D., & Schiffer, C. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.008 · Cited by 11
HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients
Burgess, M. L., Chen, Y.-C. E., Mapp, S., Blumenthal, A., Mollee, P. N., Gill, D. S., & Saunders, N. A. (2020) · Oncogene · doi:10.1038/s41388-020-01394-w · Cited by 11
Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia
Banerji, V., Aw, A., Robinson, S., Doucette, S., Christofides, A., & Sehn, L. H. (2020) · Current Oncology · doi:10.3747/co.27.6795 · Cited by 12
Cryptococcus gattii in Patients with Lymphoid Neoplasms: An Illustration of Evolutive Host–Fungus Interactions
Paccoud, O., Bougnoux, M., Desnos‐Ollivier, M., Varet, B. R., Lortholary, O., & Lanternier, F. (2021) · Journal of Fungi · doi:10.3390/jof7030212 · Cited by 11
Radionuclide Imaging of Invasive Fungal Disease in Immunocompromised Hosts
Lawal, I. O., Mokoala, K. M. G., Kgatle, M., Dierckx, R., Glaudemans, A. W. J. M., Sathekge, M. M., & Ankrah, A. O. (2021) · Diagnostics · doi:10.3390/diagnostics11112057 · Cited by 11
Fusarium, Scedosporium and Other Rare Mold Invasive Infections: Over Twenty-Five-Year Experience of a European Tertiary-Care Center
Ledoux, M., Dicop, E., Sabou, M., Letscher‐Bru, V., Castelain, V., Danion, F., & Herbrecht, R. (2024) · Journal of Fungi · doi:10.3390/jof10040289 · Cited by 10
Patterns of use and safety of ibrutinib in real‐life practice
Allouchery, M., Tomowiak, C., Guidez, S., Delwail, V., Delaunay, P., Lafay‐Chebassier, C., Salvo, F., & Pérault‐Pochat, M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14440 · Cited by 10
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic
Weber, M. S., Nicholas, J. A., & Yeaman, M. R. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001067 · Cited by 12
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper
Busca, A., Cattaneo, C. M., Carolis, E. D., Nadali, G., Offidani, M., Picardi, M., Candoni, A., Ceresoli, E., Criscuolo, M., Delia, M., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103203 · Cited by 10
Infections in patients with mantle cell lymphoma
Abalo, K., Ekberg, S., Andersson, T., Pahnke, S., Albertsson‐Lindblad, A., Smedby, K. E. E., Jerkeman, M., & Glimelius, I. C. (2024) · HemaSphere · doi:10.1002/hem3.121 · Cited by 9
Unexpected pathogen presenting with purulent meningitis
Bering, J., Hartmann, C., Asbury, K. L., & Vikram, H. R. (2020) · BMJ Case Reports · doi:10.1136/bcr-2019-231825 · Cited by 9
A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström’s macroglobulinemia
Patel, D., Sidana, M., Mdluli, X., Patel, V., Stapleton, A., & Dasanu, C. A. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221087730 · Cited by 9
Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study
Baucher, L., Lemiale, V., Joseph, A., Wallet, F., de Chambrun, M. P., Ferré, A., Lombardi, R., Platon, L., Contejean, A., Fuseau, C., et al. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01219-5 · Cited by 9
New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies
Girmenia, C. (2019) · F1000Research · doi:10.12688/f1000research.17836.1 · Cited by 9
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
Lew, T. E., Anderson, M. A., & Seymour, J. F. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.108 · Cited by 9
Total Knee Periprosthetic Joint Infection in the Setting of Hematologic Malignancy: Considerations for Management
Bloom, G. B., Mears, S. C., Edwards, P. K., Barnes, C. L., & Stambough, J. B. (2020) · Arthroplasty Today · doi:10.1016/j.artd.2020.04.002 · Cited by 9
B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells
Wang, Z., Yan, H., Boysen, J. C., Secreto, C. R., Tschumper, R. C., Ali, D., Guo, Q., Zhong, J., Zhou, J., Gan, H., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00690-w · Cited by 10
Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors
Epstein, D. J., Otoukesh, S., Shahid, Z., & Dadwal, S. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.05.019 · Cited by 8
Szczepienia ochronne u dorosłych chorych na nowotwory hematologiczne oraz u chorych z asplenią – zalecenia PTHiT i sekcji do spraw zakażeń PALG
Hus, I., Piekarska, A., Roliński, J., Brzeźniakiewicz‐Janus, K., Giannopoulos, K., Jamroziak, K., Piątkowska‐Jakubas, B., Wierzbowska, A., Zaucha, J. M., Giebel, S., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0016 · Cited by 10
Negative serum (1,3) -β-D-glucan has a low power to exclude Pneumocystis jirovecii pneumonia (PJP) in HIV-uninfected patients with positive qPCR
Huang, Y., Yi, J., Song, J., Du, L.-J., Li, X.-M., Cheng, L.-L., Yan, S., Li, H.-L., Liu, Y., Zhan, H., et al. (2023) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-023-00650-7 · Cited by 8
Antifungal and Oral Anticancer Therapy Drug Interactions
Gustafson, C. E., Koslosky, M., Leslie, J. K., & Walczak, C. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00386-3 · Cited by 8
TLR Signaling Rescues Fungicidal Activity in Syk-Deficient Neutrophils
Viens, A. L., Timmer, K. D., Alexander, N. J., Barghout, R., Milosevic, J., Hopke, A. R., Atallah, N. J., Scherer, A. K., Sykes, D. B., Irimia, D., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100599 · Cited by 8
Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
Maggioni, G., Fedrigo, M., Visentin, A., Carturan, E., Ruocco, V., Trentin, L., Alaibac, M., & Angelini, A. (2023) · Current Oncology · doi:10.3390/curroncol30090599 · Cited by 7
Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real‐life settings: A nationwide population‐based cohort study
Allouchery, M., Brunet, K., Tomowiak, C., Singier, A., Pambrun, É., Pariente, A., Bezin, J., Pérault‐Pochat, M., & Salvo, F. (2023) · Mycoses · doi:10.1111/myc.13676 · Cited by 7
Genetic Variation and Fungal Infection Risk: State of the Art
Lionakis, M. S. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00362-6 · Cited by 7
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Ren, L., Li, L., Zhang, L., Li, X., Fu, X., Wang, X., Wu, J., Sun, Z., Feng, X., Chang, Y., et al. (2021) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-021-01433-w · Cited by 7
Cytomegalovirus‐specific T‐cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib
de la Asunción, C. S., Terol, M. J., Saus, A., Olea, B., Giménez, E., Albert, E., López‐Jiménez, J., Andreu, R., García, D., Fox, M. L., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17732 · Cited by 7
Invasive Central Nervous System Aspergillosis in a Patient Receiving Long-term Acalabrutinib Therapy
Tawfiq, R. K., Ranganath, N., & Lehman, V. T. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.05.017 · Cited by 7
Functional proteoform group deconvolution reveals a broader spectrum of ibrutinib off-targets
Leo, I. R., Kunold, E., Audrey, A., Tampere, M., Eirich, J., Lehtiö, J., & Jafari, R. (2025) · Nature Communications · doi:10.1038/s41467-024-54654-8 · Cited by 6
Invasive Fungal Infections as a Complication of New Therapies
Pechacek, J., & Lionakis, M. S. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-122000 · Cited by 6
Atypical imaging patterns during lung invasive mould diseases: lessons for clinicians
Casutt, A., Lamoth, F., Lortholary, O., Prior, J. O., Tonglet, A., Manuel, O., Bergeron, A., & Beigelman‐Aubry, C. (2023) · European Respiratory Review · doi:10.1183/16000617.0086-2023 · Cited by 6
Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment
Olkkola, A. M., Tapaninen, T., Tornio, A., Hauta‐aho, M., Lapatto‐Reiniluoto, O., Neuvonen, M., Kiiski, J. I., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15932 · Cited by 6
Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)
Alsowaida, Y. S., Alsolami, A. A., Almangour, T. A., & Abraham, I. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2461199 · Cited by 6
Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors
Nasir, T., Lee, C., Lawrence, A. S., & Brown, J. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-226121 · Cited by 6
Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients
Vehreschild, J. J., Koehler, P. A., Lamoth, F., Prattes, J., Rieger, C. T., Rijnders, B. J. A., & Teschner, D. (2020) · Medical Mycology · doi:10.1093/mmy/myaa079 · Cited by 7
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions
Cho, H. J., Baek, D. W., Kim, J., Lee, J. M., Moon, J. H., & Sohn, S. K. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1967139 · Cited by 6
Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice
Kawata, K., Hatano, S., Baba, A., Imabayashi, K., & Baba, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1388947 · Cited by 6
Management of Older Adults with Mantle Cell Lymphoma
Romancik, J. T., & Cohen, J. B. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00765-y · Cited by 6
Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns
Reynolds, G. K., Slavin, M. A., & Teh, B. W. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1797017 · Cited by 6
Atypical Presentation of Severe Fungal Necrotizing Fasciitis in a Patient with X-Linked Agammaglobulinemia
Chear, C. T., Nallusamy, R. A., Chan, K. C., Tap, R. M., Baharin, M. F., Yahya, S. N. H. S., Krishnan, P. B., Mohamad, S. B., & Ripen, A. M. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01017-3 · Cited by 6
Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents
Buege, M. J., Kumar, A. A., Dixon, B. N., Tang, L. A., Pak, T., Orozco, J., Peterson, T. J., & Maples, K. T. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020909117 · Cited by 6
Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report
Higer, M., Cana, D., Podlech, J., Schadmand‐Fischer, S., Schwarting, A., Teschner, D., Theobald, M., Wölfel, T., & Heß, G. (2020) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02457-y · Cited by 6
The Muddied Waters of Ibrutinib Therapy
Pravda, M. S., Pravda, N. S., & Lishner, M. (2019) · Acta Haematologica · doi:10.1159/000496555 · Cited by 5
Guía para el diagnóstico y el tratamiento de la leucemia linfocítica crónica y el linfoma linfocítico de células pequeñas del Grupo Español de Leucemia Linfocítica Crónica (GELLC)
Medina, Á., Muntañola, A., Crespo, M., Ramírez, Á., Hernández‐Rivas, J., Abrisqueta, P., Alcoceba, M., Delgado, J., de la Serna, J., Espinet, B., et al. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2024.10.018 · Cited by 5
Clinical Mycology Today: Emerging Challenges and Opportunities
Little, J. S., Rauseo, A. M., Zuniga-Moya, J. C., Spec, A., Pappas, P. G., Perfect, J. R., McCarthy, T., & Schwartz, I. S. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae363 · Cited by 5
Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
Alsuliman, T., Faict, S., Malard, F., Genthon, A., Brissot, É., de Wyngaert, Z. V., Ikhlef, S., Banet, A., Lapusan, S., Sestili, S., et al. (2020) · Current Research in Translational Medicine · doi:10.1016/j.retram.2020.103273 · Cited by 5
How I manage infection risk and prevention in patients with lymphoid cancer
Law, N., & Taplitz, R. A. (2021) · Blood · doi:10.1182/blood.2019003687 · Cited by 5
Reporting infectious complications in haematology clinical trials should be improved
Cordonnier, C., Maschmeyer, G., Cesaro, S., & Ljungman, P. T. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.07.024 · Cited by 5
Risk of infection associated with new therapies for lymphoproliferative syndromes
Arcos, I. L., & Ruíz-Camps, I. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.07.006 · Cited by 5
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos
García‐Vidal, C., Vázquez, L., & Jarque, I. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.03.001 · Cited by 5
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity
Luppi, M., Forghieri, F., & Potenza, L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa323 · Cited by 5
Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors
Robak, E., & Robak, T. (2026) · Cancers · doi:10.3390/cancers18030371 · Cited by 5
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia
Tawfiq, R. K., Abeykoon, J. P., & Kapoor, P. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00731-0 · Cited by 4
Neutrophils unveiled in chronic lymphocytic leukemia
McManus, S. D., Khare, P., & Bertilaccio, M. T. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609754 · Cited by 4
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review
Arustamyan, M., Kibrik, P., Hatipoğlu, D., Bungo, B., Mentias, A. G., Hill, B. T., & Moudgil, R. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13854 · Cited by 4
Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions
Wonnaparhown, A. M., Hilal, T., Chong, A. C., & Fonseca, R. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101316 · Cited by 4
Cryptococcosis in Patients with Hematologic Diseases
Guaraná, M., Vidal, J. E., & Nucci, M. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0332-y · Cited by 4
A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context
Rooij, N. V., Johnston, J., Mortimore, R. J., & Robertson, I. M. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.04.022 · Cited by 4
Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial
Zhou, D., Xu, W., Ma, H., Zhao, C., Hu, Y., Zhao, Y., Wu, D., Zhao, X., He, Y., Yan, J., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-021-01206-2 · Cited by 4
Incidence of Pneumocystis jirovecii pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis
Davis, J. A., Graham, A., Hendrickson, L., Hess, B. T., & Gaffney, K. J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056179 · Cited by 4
Babesia microti-induced fulminant sepsis in an immunocompromised host: A case report and the case-specific literature review
Conte, H. A., Biondi, M., Janket, S., Ackerson, L. K., & Diamandis, E. P. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0448 · Cited by 4
Tyrosine-Kinase Inhibitors
Abad, C. L. R., & Razonable, R. R. (2022) · Springer eBooks · doi:10.1007/978-3-031-11363-5_15 · Cited by 4
Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review
Yan, Z., Luo, X., Yao, S., Wang, H., Chu, J., Zhao, S., Song, M., Wei, X.-D., Zhou, K., Li, Y., et al. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.04.003 · Cited by 4
Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran’s healthcare administration
Walker, C., Horowitz, A., Nooruddin, Z. I., & Frei, C. R. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231181113 · Cited by 4
Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature
Nguyen, T. M., Amenta, E. M., Chapman, L. O., Yellapragada, S. V., Krishnan, B., Lim, J. S., & Hamill, R. J. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241241199 · Cited by 4
Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation
McMasters, M., Blair, B. M., Lazarus, H. M., & Alonso, C. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100779 · Cited by 4
CNS infections in patients with hematological or oncological diseases (including cellular therapies) – 2024 update of the guideline of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Akdas, R., Schalk, E., Stemler, J., Schwartz, S., Meyding‐Lamadé, U., Panse, J., Krüger, W., Rohde, H., Ruhnke, M., Christopeit, M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116103 · Cited by 5
Infections in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib: Incidence and Predisposing Factors
Dmitrieva, E. A., Nikitin, E. A., Markova, E. E., Dmitrieva, N. Y., & Ptushkin, V. V. (2019) · Clinical oncohematology · doi:10.21320/2500-2139-2019-12-4-438-448 · Cited by 3
An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia
Lim, K. J. C., & Tam, C. S. L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1770727 · Cited by 3
Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma
Steffanoni, S., & Batchelor, T. T. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000993 · Cited by 3
Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria
Egger, M., Gornicec, M., Wölfler, A., Lembeck, A. L., Tinchon, C., Maderdonner, M., & Prattes, J. (2022) · Medical Mycology · doi:10.1093/mmy/myac061 · Cited by 3
Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study
Yasu, T., Sakurai, K., Hoshino, M., & Akazawa, M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2161305 · Cited by 3
Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data
Yang, H., Ding, Z., & An, Z. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2251376 · Cited by 3
Malignant syphilis in HIV negative patient treated with ibrutinib
Espinar, M. A., Merlán-Hermida, A., Suárez-Hormiga, L., & Pérez-Arellano, J.-L. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/027.2023 · Cited by 3
Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy
Nelson, T. A., Murthy, N. K., Martinez‐Lage, M., Abramson, J. S., Branagan, A. R., Ji, Y., Chen, Y.-B. A., Letourneau, A. R., Nahed, B. V., Arrillaga‐Romany, I., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209929 · Cited by 3
Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what’s best for patient quality of life?
Korycka, A., Wołowiec, D., Ławnicka, H., & Robak, T. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2471508 · Cited by 4
Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations
Carda, J. P., Santos, L., Mariz, J., Monteiro, P. F., Gonçalves, H., Raposo, J., & da Silva, M. G. (2021) · Hematology · doi:10.1080/16078454.2021.1980690 · Cited by 3
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
Vitale, C., Gibbons, J., & Ferrajoli, A. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s303060 · Cited by 3
Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
Hoang, T. A., Cheung, M. C., Juurlink, D. N., Chan, K., Lau, C., Liu, N., Abdel-Qadir, H. M., Prica, A. A., Hay, A. E., Vijenthira, A., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70131 · Cited by 2
Discovery of Pyrazoline Benzenesulfonamide Derivatives as Anticancer Agents: A Review
Hasyim, D. M., Musfiroh, I., Hendra, R., Kamarulzaman, E. E., Ritmaleni, R., & Muchtaridi, M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s562109 · Cited by 2

Authors: Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Infectious Diseases Service, Memorial Sloan Kettering Cancer Center
ORCID: Taur, Ying
Cohen, Nina
Palomba, M Lia
Seo, Susan K
Hohl, Tobias M
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2018-04-27
Volume: 67
Issue: 5
Pages: 687-692
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1093/cid/ciy175
PMC: PMC6093991
OpenAlex: W2789508123
Cited by: 271
References: 36
Citations by year: 2026: 14 · 2025: 23 · 2024: 25 · 2023: 25 · 2022: 26 · 2021: 50 · 2020: 56 · 2019: 36 · 2018: 15
FWCI: 14.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: Clinical Infectious Diseases (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30 CA008748)
National Institutes of Health (K08 CA184038)
Topics: Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords: ibrutinib, serious infections, lymphoid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, BTK inhibitors, invasive fungal infections, invasive bacterial infection, infection risk factors, opportunistic infections
MeSH terms: Invasive Fungal Infections, Adenine, Adult, Aged, Aged, 80 and over, Bacterial Infections, Female, Humans, Lymphopenia, Male, Middle Aged, New York, Opportunistic Infections, Piperidines, Pyrazoles, Pyrimidines, Risk Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Young Adult, Electronic Health Records

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks